Drug Trial Radar · NCT06947993
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
224
Planned (sponsor's estimate)
Start
May 16, 2025
Primary completion
Nov 27, 2028
Study completion Dec 22, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Conditions
- Atopic Dermatitis
Interventions
GHZ339Drug
GHZ339 administered at dose A, B, C and D
PlaceboDrug
Matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the Eczema Area and Severity Index (EASI) score at Week 16Time frame: Baseline, Week 16
Locations
105 sites in 17 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama · Recruiting
Novartis Investigative Site
Birmingham, Alabama · Recruiting
Novartis Investigative Site
Fort Smith, Arkansas · Recruiting
Novartis Investigative Site
Fountain Valley, California · Recruiting
Novartis Investigative Site
Los Angeles, California · Recruiting
Novartis Investigative Site
Sacramento, California · Recruiting
Novartis Investigative Site
Santa Ana, California · Recruiting
Novartis Investigative Site
Santa Monica, California · Recruiting
Novartis Investigative Site
Washington D.C., District of Columbia · Recruiting
Novartis Investigative Site
Miami, Florida · Recruiting
Novartis Investigative Site
St. Petersburg, Florida · Recruiting
Novartis Investigative Site
Atlanta, Georgia · Recruiting
Novartis Investigative Site
Macon, Georgia · Recruiting
Novartis Investigative Site
Louisville, Kentucky · Recruiting
Novartis Investigative Site
Brighton, Massachusetts · Recruiting
Novartis Investigative Site
Troy, Michigan · Recruiting
Novartis Investigative Site
Saint Joseph, Missouri · Recruiting
Novartis Investigative Site
Portsmouth, New Hampshire · Recruiting
Novartis Investigative Site
Brooklyn, New York · Recruiting
Novartis Investigative Site
Arlington, Texas · Recruiting
Novartis Investigative Site
Cypress, Texas · Recruiting
Novartis Investigative Site
Dallas, Texas · Recruiting
Novartis Investigative Site
Houston, Texas · Recruiting
Novartis Investigative Site
San Antonio, Texas · Recruiting
Novartis Investigative Site
Caba, Buenos Aires, Argentina · Recruiting
Novartis Investigative Site
Caba, Buenos Aires, Argentina · Recruiting
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina · Recruiting
Novartis Investigative Site
Edmonton, Alberta, Canada · Active not recruiting
Novartis Investigative Site
Hamilton, Ontario, Canada · Recruiting
Novartis Investigative Site
Markham, Ontario, Canada · Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada · Recruiting
Novartis Investigative Site
Verdun, Quebec, Canada · Active not recruiting
Novartis Investigative Site
Beijing, China · Withdrawn
Novartis Investigative Site
Beijing, China · Active not recruiting
Novartis Investigative Site
Shanghai, China · Recruiting
Novartis Investigative Site
Guangzhou, Guangdong, China · Active not recruiting
Novartis Investigative Site
Shantou, Guangdong, China · Active not recruiting
Novartis Investigative Site
Changsha, Hunan, China · Active not recruiting
Novartis Investigative Site
Changchun, Jilin, China · Active not recruiting
Novartis Investigative Site
Hangzhou, Zhejiang, China · Recruiting
Showing 40 of 105 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.